Effect of periodontal treatment on the clinical parameters of patients with rheumatoid arthritis: study protocol of the randomized, controlled ESPERA trial

• Published in: Trials Vol. 14; no. 1; p. 253
• Main Authors: Monsarrat, Paul, Vergnes, Jean-Noël, Cantagrel, Alain, Algans, Nadège, Cousty, Sarah, Kémoun, Philippe, Bertrand, Caroline, Arrivé, Elise, Bou, Christophe, Sédarat, Cyril, Schaeverbeke, Thierry, Nabet, Cathy, Sixou, Michel
• Format: Journal Article
• Language: English
• Published: London BioMed Central 14.08.2013; BioMed Central Ltd
• Subjects: Anti-Bacterial Agents - therapeutic use; Anti-Infective Agents, Local - therapeutic use; Arthritis, Rheumatoid - diagnosis; Arthritis, Rheumatoid - immunology; Arthritis, Rheumatoid - therapy; Biomedicine; C-reactive protein; Care and treatment; Clinical Protocols; Clinical trials; Dental Scaling; Dermatology; Engineering Sciences; France; Health Sciences; Hospitals, University; Human health and pathology; Humans; Life Sciences; Medicine; Medicine & Public Health; Oral Hygiene; Patient outcomes; Periodontal disease; Periodontitis - diagnosis; Periodontitis - immunology; Periodontitis - microbiology; Periodontitis - therapy; Plasmas; Predictive Value of Tests; Quality of Life; Research Design; Rheumatoid arthritis; Risk factors; Root Planing; Sensory Organs; Severity of Illness Index; Statistics for Life Sciences; Study Protocol; Surgery; Surveys and Questionnaires; Time Factors; Toiletries industry; Treatment Outcome; France; Periodontal diseases; Periodontitis; Protocol; Randomized controlled trial; Rheumatoid arthritis
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/1745-6215-14-253

Background Rheumatoid arthritis (RA) is a chronic inflammatory disorder that leads to joint damage, deformity, and pain. It affects approximately 1% of adults in developed countries. Periodontitis is a chronic oral infection, caused by inflammatory reactions to gram-negative anaerobic bacteria, and affecting about 35 to 50% of adults. If left untreated, periodontitis can lead to tooth loss. A significant association has been shown to exist between periodontitis and RA in observational studies. Some intervention studies have suggested that periodontal treatment can reduce serum inflammatory biomarkers such as C-reactive protein, or erythrocyte sedimentation rate. We hypothesize that periodontitis could be an aggravating factor in patients with RA, and that its treatment would improve RA outcomes. The aim of this clinical trial is to assess the effect of periodontal treatment on the biological and clinical parameters of patients with RA. Methods/design The ESPERA (Experimental Study of Periodontitis and Rheumatoid Arthritis) study is an open-label, randomized, controlled trial. Subjects with both RA and periodontitis will be recruited at two university hospitals in southwestern France. In total, 40 subjects will be randomized into two arms (intervention and control groups), and will be followed up for 3 months. Intervention will consist of full-mouth supra-gingival and sub-gingival non-surgical scaling and root planing, followed by systemic antibiotic therapy, local antiseptics, and oral hygiene instructions. After the 3-month follow-up period, the same intervention will be applied to the subjects randomized to the control group. The primary outcome will be change of in Disease Activity Score in 28 Joints (DAS28) at the end of the follow-up period. Secondary outcomes will be the percentages of subjects with 20%, 50%, and 70% improvement in disease according to the American College of Rheumatology criteria. Health-related quality of life assessments (the Health Assessment Questionnaire and the Geriatric Oral Health Assessment Index) will also be compared between the two groups. Discussion Evidence-based management of potential aggravating factors in subjects with active RA could be of clinical importance, yet there are few randomized controlled trials on the effect of periodontal treatment on the clinical parameters of RA. The ESPERA trial is designed to determine if non-surgical periodontal treatment could improve clinical outcomes in patients with active RA, and the quality of life of these patients. Trial registration The ESPERA Trial was registered in Current Controlled Trials [ ISRCTN79186420 ] on 2012/03/20. The trial started recruiting on 2012/03/06.